Stocks · Health care · Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc.

GLUE Clue Score47

United States Fiscal year ends December CIK 0001826457 Results filed 5 Nov 2026

Add to watchlist

By person

10 insiders · 37 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Filip Janku

Chief Medical Officer

—

$1.38M (6) scheduled

−$1.38M

60,612

0.0710%

$640.06K

+413.6%

Markus Warmuth

President & CEO

—

$951.14K (10)

−$951.14K

585,038

0.6858%

$6.18M

+40.5%

Edmund Dunn

Principal Accounting Officer

—

$483.14K (4) scheduled

−$483.14K

22,554

0.0264%

$238.17K

+61.7%

Sharon Townson

Chief Scientific Officer

—

$423.93K (6) scheduled

−$423.93K

67,845

0.0795%

$716.44K

—

Anthony M. Manning

Director

—

$411.20K (2) scheduled

−$411.20K

0.0000%

$0.00

—

Jennifer Champoux

Chief Operating Officer

—

$311.30K (6) scheduled

−$311.30K

62,371

0.0731%

$658.64K

—

Philip Nickson

Chief Business & Legal Officer

—

$151.27K (2)

−$151.27K

55,000

0.0645%

$580.80K

—

Matthew Bowen

Principal Accounting Officer

—

$137.28 (1)

−$137.28

25,891

0.0303%

$273.41K

+19.8%

Chandra P. Leo

Director

—

10,000

0.0117%

$105.60K

—

Ali Behbahani

Director

—

0.0000%

$0.00

−100.0%

Monte Rosa Therapeutics, Inc.

What the insiders did Net selling

By person